ROSEN, LEADING INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

Rosen Law Firm has filed a class action lawsuit against Capricor Therapeutics (CAPR) on behalf of investors who purchased securities between December 17, 2025 and July 26, 2026. The lawsuit alleges that Capricor made materially false statements regarding changes to its statistical analysis plan for Deramiocel without FDA approval, creating significant regulatory risk for the cell therapy's approval for treating Duchenne muscular dystrophy. Investors must move the court by September 28, 2026 to serve as lead plaintiff.